Abiraterone oral - Bukwang Pharmaceuticals

Drug Profile

Abiraterone oral - Bukwang Pharmaceuticals

Alternative Names: SOL-804

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solural Pharma
  • Class Antiandrogens; Antineoplastics
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 04 Oct 2017 Bukwamg Pharmaceuticals plans a phase I trial for Prostate cancer (Bunkwang Pharmaceuticals pipeline, October 2017)
  • 08 Dec 2015 SOL 804 is available for licensing as of 08 Dec 2015. http://soluralpharma.com/project/
  • 08 Dec 2015 Preclinical trials in Prostate cancer in Denmark (PO) prior to December 2015 (Solural pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top